Connection

Gionata Fiorino to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Gionata Fiorino has written about Antibodies, Monoclonal.
Gionata Fiorino
Connection Strength
0.523
Antibodies, Monoclonal
  1. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):601-606.
    View in: PubMed
    Score: 0.182
  2. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis. 2017 02; 23(2):233-243.
    View in: PubMed
    Score: 0.170
  3. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. Curr Med Chem. 2019; 26(2):280-287.
    View in: PubMed
    Score: 0.048
  4. Are Surgical Rates Decreasing in the Biological Era In IBD? Curr Drug Targets. 2019; 20(13):1356-1362.
    View in: PubMed
    Score: 0.048
  5. The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017 Apr; 16(4):437-443.
    View in: PubMed
    Score: 0.043
  6. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Dig Liver Dis. 2019 04; 51(4):510-515.
    View in: PubMed
    Score: 0.012
  7. Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? Dig Dis Sci. 2017 11; 62(11):2964-2965.
    View in: PubMed
    Score: 0.011
  8. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014 Nov; 8(11):1548-50.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.